Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798820 | 0.93 | CYSLTR2 (0.53) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL2514450 | 0.91 | KCNH2 (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL6115301 | 0.91 | KCNH2 (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL6114801 | 0.91 | KCNH2 (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL6114960 | 0.91 | KCNH2 (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL16289622 | 0.91 | PDE10A (0.45) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL1551574 | 0.91 | CYSLTR1 (0.45) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL6115276 | 0.91 | KCNH2 (0.61) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL9480330 | 0.91 | PDE10A (0.45) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 | |
| SCHEMBL11693824 | 0.91 | PDE10A (0.45) | CYSLTR2CYSLTR1PDE10ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | WASHINGTON UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | CYSLTR2 3151/4885CYSLTR1 2453/4885PDE10A 3587/4885 |
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | NADK, NAPRT, TIPARP | CYSLTR2 3151/4885CYSLTR1 2453/4885PDE10A 3587/4885 |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | CYSLTR2 3151/4885CYSLTR1 2453/4885PDE10A 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.